Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Is bradykinin responsible for the covid-19 cough?

Written by | 26 Aug 2020

Article written by Christine Clark The similarities between the ACE-inhibitor cough and the cough of covid-19 prompted Dr Colin Brown, a retired GP and researcher, to investigate further…. read more.

The link between ACE-inhibitor cough and covid-19 cough

Written by | 24 Aug 2020

Article written by Christine Clark Retired GP and researcher Dr Colin Brown realised that the similarities between the ACEI cough and covid-19 cough suggested a common cause and… read more.

Have Pharma gone Webinar crazy!?

Written by | 19 Aug 2020

Article written by Peter Mas-Mollinedo With the outbreak of the Pandemic and the lingering worries of COVID-19 pharmaceutical sales and marketing has taken a hit. There are no… read more.

Telehealth visits have skyrocketed for older adults, but some concerns & barriers remain

Written by | 17 Aug 2020

One in four older Americans had a virtual medical visit in the first three months of the COVID-19 pandemic, most of them by video, a new telehealth poll finds. 

Coronavirus lockdown avoided 700,000 cases in 50 days

Written by | 6 Aug 2020

Article written by Gary Finnegan China’s control measures during the first 50 days of the COVID-19 epidemic may have delayed the spread of the virus to cities outside… read more.

Smokers and COPD patients suffer more and die more from COVID-19

Written by | 29 Jul 2020

Article written by Bruce Sylvester. Current smokers and those with chronic obstructive pulmonary disease COPD suffer greater COVID-19 severity and greater COVID-19 related mortality..

Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal phase II/III global study.

Written by | 29 Jul 2020

Pfizer Inc. and BioNTech SE announced the start of a global (except for China) Phase II/III safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA… read more.

Health Canada approves Velkury to treat pneumonia associated with COVID-19. -Gilead Sciences

Written by | 29 Jul 2020

Health Canada has approved, with conditions, remdesivir (Velkury) from Gilead Sciences to treat COVID-19 patients. Remdesivir is used to treat those with pneumonia who need extra oxygen to… read more.

Phase III trial of mRNA 1273 in coronavirus expanded in US.- Moderna

Written by | 27 Jul 2020

Moderna announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late… read more.

Phase III results show antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of Covid-19 compared to placebo. – Glenmark Pharma

Written by | 26 Jul 2020

Glenmark announced Phase III results that showed its antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of COVID-19 compared to placebo . Favipiravir is a broad-spectrum oral… read more.

Trial of SNG 001 shows positive results in COVID-19 patients.- Synairgen

Written by | 21 Jul 2020

Synairgen announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. The double-blind placebo-controlled trial recruited 101 patients… read more.

Phase I/II COV001 trial of AZD 1222 shows vaccine well tolerated in SARS-CoV-2 virus.- AstraZeneca

Written by | 21 Jul 2020

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD 1222 vaccine, from AstraZeneca, was tolerated and generated robust immune responses against the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.